Current Report Filing (8-k)
October 22 2018 - 6:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October
22, 2018
(
October 19, 2018)
Heyu
Biological Technology Corporation
(Exact Name of Registrant as Specified in its
Charter)
Nevada
|
|
000-26731
|
|
87-0627910
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
4th Floor, No. 10 Building, Xinglin Bay Business
Operation Center,
Jimei District, Xiamen City,
Fujian Province, China 361022
(Address of Principal Executive Offices, Zip
Code)
Registrant’s telephone number, including
area code:
(86) 158 5924 0902
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On October 19, 2018, Heyu
Biological Technology Corporation (the “Company”) entered into a non-binding letter of intent with Luoyang Ditiantai
Agricultural Development Co., Ltd. (the “Target”), a Chinese industrial agricultural chain enterprise, pursuant to
which the Company agreed to acquire 51 percent (51%) of the outstanding capital of the Target subject to certain adjustment provisions
(the “Acquisition”).
The closing of the Acquisition is subject
to customary terms and conditions, including, but not limited to, completion of due diligence, negotiation and execution of definitive
transaction documents between the parties and the delivery of audited and unaudited financial statements of the Target as required
under applicable rules of the Securities and Exchange Commission. In addition, completion of the transaction is subject to approval
by our board of directors.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Heyu Biological Technology Corporation
|
|
|
|
By:
|
/s/
Ban Siong Ang
|
|
Name:
Title:
|
Ban Siong Ang
Chief Executive Officer
|
|
|
|
|
Dated:
|
October 22, 2018
|
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Apr 2023 to Apr 2024